A new review paper was published in the journal Oncotarget on March 31, 2023, titled “Crosstalk between triple negative breast cancer and microenvironment.”
Although many advances have been made in the treatment of breast cancer, for triple negative breast cancer (TNBC) these therapies have not significantly increased overall survival. The tumor microenvironment (TME) plays an essential role in developing and controlling TNBC progression. Many preclinical and clinical studies are ongoing to treat patients with TNBC disease, but effective therapies are currently not available.
In their new review, researchers Karly Smrekar, Artem Belyakov and Kideok Jin from the Albany College of Pharmacy and Health Science discuss recent progress in our understanding of TNBC, advancements in defining mechanisms of TNBC therapies and potential therapeutic strategies to overcome TNBC.
“Technological advancements such as genomics and epigenomics have provided us with vast insight about the complexity of breast cancer. However, one thing has remained the same, the need for the evaluation of three markers. These three markers; the expression of estrogen, progesterone, and HER2, are all molecular targets for treatment regimens, and are relied on by clinicians. Chemotherapy is the staple treatment for TNBC patients. However, they lack the expression of three key therapeutic markers. The lack of therapeutic markers leads to poorer outcomes in TNBC,” state the authors.
More information:
Karly Smrekar et al, Crosstalk between triple negative breast cancer and microenvironment, Oncotarget (2023). DOI: 10.18632/oncotarget.28397
Journal information:
Oncotarget
Source: Read Full Article